BioSpace News Archive

Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the results from a clinical study in children using a wearable myopia control device based on Kubota Glass technology.

According to the current analysis of Reports and Data, the Pressure Ulcers Treatment market was valued at USD 5.36 billion in 2019 and is expected to reach USD 12.73 billion by the year 2027, at a CAGR of 11.4%.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen1 phase 3 clinical trial will be presented at the American Rhinologic Society (ARS) 68th Annual Meeting in Philadelphia, Pennsylvania on September 9, 2022.

Cytovia Therapeutics, Inc. released the following statement on the passing of Olivier Gouédard, PharmD, MBA, who served as its Chief Operating Officer for the past year.

Evolve Biologics Inc., an innovative plasma-derived therapeutics company, is pleased to announce the appointment of Chris Carr as Chief Financial Officer.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, announced that the company’s management team will participate at the following conferences in September 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Rarecells, Inc. announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director.

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced exciting new preclinical data from the University of Tennessee Graduate School of Medicine from its study on novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance.

Iovance Biotherapeutics, Inc. announced the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte cell therapies at the European Society for Medical Oncology Congress 2022 in Paris, France, September 9 – 13, 2022.